Comparison of Depression Identification After Acute Coronary Syndrome: Quality of Life and Cost Outcomes

• Status: Completed
• Trial end date: 2019-07-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to examine, in a randomized controlled trial, the benefits and costs of the American Heart Association's (AHA) advisory for depression screen and treatment of post-acute coronary syndrome patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Columbia University
• Collaborators: Duke University; HealthPartners Institute; Kaiser Foundation Research Institute; National Heart, Lung, and Blood Institute (NHLBI)
• Treatments: Antidepressive Agents; Bupropion; Sertraline

Criteria

Inclusion Criteria:

• With a documented acute coronary syndrome (ACS) within the past 2-12 months

• Over the age of 21 years

• Has access to a phone

Exclusion Criteria:

Medical Exclusions:

• Terminal illness (life expectancy <1 year as determined by physician/medical record) defined as, but not limited to:

• NYHA class IV, ACC class D CHF requiring inotropes or mechanical assist devices or critical aortic stenosis without plan for correction

• End-stage COPD/emphysema

• Advanced cirrhosis with encephalopathy, varices, severe ascites

• Severe rheumatologic diseases requiring frequent hospitalizations, and multiple cytotoxic agents and/or disease modifying drugs

• Metastatic pancreatic, esophageal, colorectal or stomach cancer

• Metastatic sarcoma, ovarian, melanoma or renal cell cancer

• Metastatic breast cancer with multiple recurrences despite treatment

• Advanced CNS malignancies

• Recurrent hematologic malignancies with multiple recurrences despite treatment

• Persistent AIDS, untreated or treated

Psychiatric Exclusions:

• History of major depression

• Currently receiving depression treatment

• Dementia

• History of bipolar disorder

• History of psychosis

• History of suicide attempt or self-inflicted injuries

• Current alcohol or substance abuse

Other Exclusions:

• Non-English and non-Spanish speaking